文献速递中医内科中药与中成药合理使用

中药治疗痛性糖尿病周围神经病变的系统评价与Meta分析

The efficacy and safety of Chinese herbal medicine in the treatment of painful diabetic neuropathy: A systematic review and meta-analysis.
PubMed 文献 · Front Pharmacol · 2023-03-06

该系统评价与Meta分析检索随机对照试验,评估中药治疗痛性糖尿病周围神经病变的有效性与安全性,共纳入21项RCT、1737例参与者。结果显示中药可改善多条神经传导速度、提高临床有效率、降低疼痛评分与中医证候评分,且不良事件较少,但需更高质量研究验证。

要点

  • 中药可改善痛性糖尿病周围神经病变患者多条神经传导速度。
  • 中药可提高临床有效率并降低疼痛评分与中医证候评分。
  • 中药干预不良事件少于对照组,安全性较好。

核心结论

  • 中药作为辅助治疗或单一治疗对痛性糖尿病周围神经病变患者疗效较好且安全,值得临床推广使用,但仍需更高质量临床研究证明。

研究设计与样本

  • 系统评价与Meta分析,检索随机对照试验,共纳入21项RCT、1737例参与者,使用Stata 16.0进行Meta分析。

主要发现

  • 中药可改善正中神经SCV(MD=3.56,95%CI 2.19~4.92)与MCV(MD=3.82,95%CI 2.51~5.12)。
  • 中药可改善腓总神经SCV(MD=4.16,95%CI 1.62~6.70)与MCV(MD=4.37,95%CI 1.82~6.93)。
  • 中药可改善腓肠神经SCV(MD=4.95,95%CI 3.52~6.37)与胫神经MCV(MD=6.30,95%CI 5.00~7.60)。
  • 中药提高临床有效率(OR=4.00,95%CI 2.89~5.52),降低疼痛评分(SMD=-2.23,95%CI -3.04~-1.41)与中医证候评分(MD=-4.70,95%CI -6.61~-2.80)。
  • 与对照组相比,中药干预的不良事件发生更少。

关键数值与推荐

  • 临床有效率OR=4.00,95%CI 2.89~5.52。
  • 疼痛评分SMD=-2.23,95%CI -3.04~-1.41。
  • 中医证候评分MD=-4.70,95%CI -6.61~-2.80。

临床怎么用

  • 可考虑将中药作为痛性糖尿病周围神经病变的辅助治疗或单一治疗以改善神经传导和临床症状。
  • 临床应用时需结合患者证候与中药安全性监测,并注意证据质量限制。

局限性

  • 仍需更高质量的临床研究证明中药对痛性糖尿病周围神经病变的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: The objective of this systematic review and meta-analysis is to assess the effectiveness and security of Chinese herbal medicine (CHM) in the therapy of painful diabetic neuropathy (PDN). Methods: We searched databases for randomized controlled trials (RCTs) of CHM in the treatment of PDN. Outcome indicators included nerve conduction velocity, clinical efficiency, pain score, TCM syndrome score, and adverse events. Stata 16.0 was used to carry out the Meta-analysis. Results: A total of 21 RCTs with 1,737 participants were included. This meta-analysis found that using CHM as adjuvant treatment or as monotherapy for PDN can improve SCV of median nerve [mean difference (MD) = 3.56, 95% Confidence interval (CI) (2.19, 4.92) ], MCV of median nerve [ MD = 3.82, 95% CI (2.51, 5.12) ], SCV of common peroneal nerve [ MD = 4.16, 95% CI (1.62, 6.70) ], MCV of common peroneal nerve [ MD = 4.37, 95% CI (1.82, 6.93) ], SCV of gastrocnemius nerve [ MD = 4.95, 95% CI (3.52, 6.37) ], SCV of tibial nerve [ MD = 3.17, 95% CI (-2.64, 8.99) ], MCV of tibial nerve [MD = 6.30, 95%CI (5.00, 7.60)] and clinical effective rate [ odds ratio (OR) = 4.00, 95% CI (2.89, 5.52) ] and reduce pain score [standardized mean difference (SMD) = -2.23, 95% CI (-3.04, -1.41) ], TCM syndrome score [ MD = -4.70, 95% CI (-6.61, -2.80) ]. In addition, compared to the control group, adverse events of Chinese medicine intervention occurred less. Conclusion: CHM as adjuvant therapy or single treatment has a good curative effect and is safe for patients with PDN, which is worthy of clinical promotion and use, however; higher quality clinical studies are still needed to prove. Systematic Review Registration: https://www.crd.york.ac.uk/, identifier CRD42022327967.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Song M, Huai B, Shi Z, et al. The efficacy and safety of Chinese herbal medicine in the treatment of painful diabetic neuropathy: A systematic review and meta-analysis. Front Pharmacol. 2023. PMID: 36950007. doi:10.3389/fphar.2023.1072991

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。